Hypothyroidism in patients with renal cell carcinoma

Cancer

Volumn 117, Issue 3, 2011, Pages 534-544

  Schmidinger, Manuela ^a   Vogl, Ursula M ^a   Bojic, Marija ^a   Lamm, Wolfgang ^a   Heinzl, Harald ^a   Haitel, Andrea ^a   Clodi, Martin ^a   Kramer, Gero ^a   Zielinski, Christoph C ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

hypothyroidism; predictive factors; renal cell carcinoma; sorafenib; sunitinib

Indexed keywords

BEVACIZUMAB; CYTOKINE; LEVOTHYROXINE; LIOTHYRONINE; SORAFENIB; SUNITINIB; THYROTROPIN; THYROXINE; VASCULOTROPIN ANTIBODY;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER REGRESSION; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED STUDY; EUTHYROIDISM; FEMALE; HUMAN; HYPOTHYROIDISM; KIDNEY CARCINOMA; LIOTHYRONINE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; SURVIVAL RATE; THYROID FUNCTION TEST; THYROTROPIN BLOOD LEVEL; THYROXINE BLOOD LEVEL; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; HYPOTHYROIDISM; INDOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; PYRIDINES; PYRROLES; THYROTROPIN; TREATMENT OUTCOME;

EID: 78651361788     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25422     Document Type: Article

References (40)

1. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004; 64: 7099-7109.
2. Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res. 2003; 9: 327-337.
3. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007; 356: 115-124.
4. McCubrey JA, Steelman LS, Chappell WH, et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta. 2007; 1773: 1263-1284.
5. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007; 356: 125-134.
6. Motzer RJ, Agarwal N, Beard C, et al. NCCN clincal practice guidelines in oncology: kidney cancer. J Natl Comper Canc Netw. 2009; 7: 618-630.
7. Hutson TE, Figlin RA, Kuhn JG, Motzer RJ., Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies. Oncologist. 2008; 13: 1084-1096.
8. Schmidinger M, Zielinski CC, Vogl UM, et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2008; 26: 5204-5212.
9. Rini BI, Tamaskar I, Shaheen P, et al. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst. 2007; 99: 81-83.
10. Tamaskar I, Bukowski R, Elson P, et al. Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib. Ann Oncol. 2008; 19: 265-268.
11. Wolter P, Stefan C, Decallonne B, et al. The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation. Br J Cancer. 2008; 99: 448-454.
12. Baffert F, Le T, Thurston G, McDonald DM., Angiopoietin-1 decreases plasma leakage by reducing number and size of endothelial gaps in venules. Am J Physiol Heart Circ Physiol. 2006; 290: H107-H118.
13. Kamba T, Tam BY, Hashizume H, et al. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol. 2006; 290: H560-H576.
14. Skinner MA, Safford SD, Freemerman AJ., RET tyrosine kinase and medullary thyroid cells are unaffected by clinical doses of STI571. Anticancer Res. 2003; 23 (5A): 3601-3606.
15. Mannavola D, Coco P, Vannucchi G, et al. A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake. J Clin Endocrinol Metab. 2007; 92: 3531-3534.
16. Wong E, Rosen LS, Mulay M, et al. Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity. Thyroid. 2007; 17: 351-355.
17. Fagin JA., How thyroid tumors start and why it matters: kinase mutants as targets for solid cancer pharmacotherapy. J Endocrinol. 2004; 183: 249-256.
18. Gupta-Abramson V, Troxel AB, Nellore A, et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol. 2008; 26: 4714-4719.
19. Davis FB, Tang HY, Shih A, et al. Acting via a cell surface receptor, thyroid hormone is a growth factor for glioma cells. Cancer Res. 2006; 66: 7270-7275.
20. Theodossiou C, Skrepnik N, Robert EG, et al. Propylthiouracil-induced hypothyroidism reduces xenograft tumor growth in athymic nude mice. Cancer. 1999; 86: 1596-1601.
21. Goodman AD, Hoekstra SJ, Marsh PS., Effects of hypothyroidism on the induction and growth of mammary cancer induced by 7,12-dimethylbenz(a)anthracene in the rat. Cancer Res. 1980; 40: 2336-2342.
22. Mishkin SY, Pollack R, Yalovsky MA, Morris HP, Mishkin S., Inhibition of local and metastatic hepatoma growth and prolongation of survival after induction of hypothyroidism. Cancer Res. 1981; 41: 3040-3045.
23. Nelson M, Hercbergs A, Rybicki L, Strome M., Association between development of hypothyroidism and improved survival in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg. 2006; 132: 1041-1046.
24. Hercbergs A, Goyal LK, Suh JH, et al. Propylthiouracil-induced chemical hypothyroidism with high-dose tamoxifen prolongs survival in recurrent high grade glioma: a phase I/II study. Anticancer Res. 2003; 23 (1B): 617-626.
25. Hercbergs A, Werner A, Brenner HJ., Does hypothyroidism favor the response to therapy in metastatic breast cancer [abstract]? Proc ASCO. 1988; 7: A77.
26. Leibovich BC, Blute ML, Cheville JC, et al. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer. 2003; 97: 1663-1671.
27. Weijl NI, Van der Harst D, Brand A, et al. Hypothyroidism during immunotherapy with interleukin-2 is associated with antithyroid antibodies and response to treatment. J Clin Oncol. 1993; 11: 1376-1383.
28. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92: 205-216.
29. Brabant G, Beck-Peccoz P, Jarzab B, et al. Is there a need to redefine the upper normal limit of TSH? Eur J Endocrinol. 2006; 154: 633-637.
30. Motzer RJ, Bacik J, Mariani T, Russo P, Mazumdar M, Reuter V., Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol. 2002; 20: 2376-2381.
31. Wolter P., Evaluation of thyroid dysfunction as a candidate surrogate marker for efficacy of sunitinib in patients (pts) with advanced renal cell cancer (RCC) [abstract]. J Clin Oncol. 2008; 26S. Abstract 5126.
32. Trentin AG, Alvarez-Silva M, Moura Neto V., Thyroid hormone induces cerebellar astrocytes and C6 glioma cells to secrete mitogenic growth factors. Am J Physiol Endocrinol Metab. 2001; 281: E1088-E1094.
33. Surks MI, Ortiz E, Daniels GH, et al. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA. 2004; 291: 228-238.
34. Mukku VR., Regulation of epidermal growth factor receptor levels by thyroid hormone. J Biol Chem. 1984; 259: 6543-6547.
35. Wolf M, Ingbar SH, Moses AC., Thyroid hormone and growth hormone interact to regulate insulin-like growth factor-I messenger ribonucleic acid and circulating levels in the rat. Endocrinology. 1989; 125: 2905-2914.
36. Bergh JJ, Lin HY, Lansing L,et al. Integrin alphaVbeta3 contains a cell surface receptor site for thyroid hormone that is linked to activation of mitogen-activated protein kinase and induction of angiogenesis. Endocrinology. 2005; 146: 2864-2871.
37. Houk B, Bello CL, Michaelson MD, et al. A population pharmacokinetic/ pharmacodynamic (PK/PD) analysis of exposure-response for sunitinib in metastatic renal cell carcinoma (mRCC) [abstract]. Eur J Cancer. 2007; 5 (suppl): 299. Abstract 4505.
38. Gordan JD, Lal P, Dondeti VR, et al. HIF-alpha effects on c-Myc distinguish 2 subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell. 2008; 14: 435-446.
39. Rini BI, Schiller JH, Fruehaf JP, et al. Association of diastolic blood pressure (dBP) >90 mm Hg with overall survival (OS) in patients treated with axitinib (AG-013736) [abstract]. J Clin Oncol. 2008; 26 (May 20 suppl). Abstract 3543.
40. Desar IM, van Herpen CM, van Laarhoven HW, Barentsz JO, Oyen WJ, van der Graaf WT,. Beyond RECIST: molecular and functional imaging techniques for evaluation of response to targeted therapy. Cancer Treat Rev. 2009; 35: 309-321.